Granules India confirms $35m US plant expansion will create jobs

By Gareth Macdonald

- Last updated on GMT

iStock/daboost
iStock/daboost
Granules India says adding manufacturing capacity at its facility in Virginia, US will create 102 jobs.

The Hyderabad, India based firm announced it would add finished dosage form manufacturing capacity at the facility in Chantilly, Virginia earlier this year​.

Granules gave more details of the project this week, explaining that it will spend $35m (€31m) on the expansion adding that it will create 102 new jobs.

Granules bought the plant from Valeant in 2014.

The firm said it “is conducting research and development to formulate products, and intends to manufacture products in the location as well​.”

The expansion is backed by the Virginia Economic Development Partnership, which provides consultative services and funding to companies creating jobs. According to Virginia Business​ Granules is eligible to receive $750 per job.

Expansions

The project is the third expansion Granules has announced this year.

In February, it said it will build an API production facility in Bonthapally, Telangana and increase capacity at a plant in Gagillapur where it produces pharmaceutical formulation intermediates (PFIs).

At the time a Granules spokesman told us “existing capacities are not sufficient to meet customer demand​” adding the new and expanded facilities will supply both local and international markets.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Webinars

Headlines